Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150211 | 0.81 | THRB (0.39) | MAPTCYP2C9ALDH1A1HTT | |
| SCHEMBL20225778 | 0.77 | CYP19A1 (0.37) | CYP19A1MAPTCYP2C9KDM4EALDH1A1 | |
| SCHEMBL20150205 | 0.75 | TDP1 (0.45) | MAPTCYP2C9ALDH1A1HTT | |
| SCHEMBL20225779 | 0.75 | HTR1D (0.38) | CYP19A1MAPTCYP2C9ALDH1A1 | |
| SCHEMBL20225763 | 0.70 | TSHR (0.53) | CYP19A1PKMMAPTKDM4EALDH1A1 | |
| SCHEMBL20150151 | 0.70 | ERN1 (0.45) | CYP19A1MAPT | |
| SCHEMBL29739895 | 0.69 | CYP19A1 (0.49) | CYP19A1MAPTKDM4EALDH1A1HTT | |
| SCHEMBL29686179 | 0.69 | TSHR (0.50) | CYP19A1PKMMAPTKDM4EALDH1A1 | |
| SCHEMBL20150149 | 0.69 | CYP19A1 (0.49) | CYP19A1MAPTKDM4EALDH1A1HTT | |
| SCHEMBL3617121 | 0.69 | CYP19A1 (0.50) | CYP19A1KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206196-A1 | PYRIMIDINE SUBSTITUTED DERIVATIVES AS TYK2 INHIBITORS | Almirall S.A. (ES) | 2023-07-05 | — | — | EP | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885PKM 1134/4885MAPT 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.